Prineo (Dermabond Protape) Versus Sutures for Full-thickness Surgical Incisions

Ethicon

Status and phase: Completed; Phase 4

Conditions: Surgical Incisions

Treatments: Device: Suture; Device: Dermabond Protape (Prineo)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00557947

06CS005

Details and patient eligibility

About

This is a prospective, controlled, randomized, multi-center clinical study of up to 80 subjects with full thickness surgical incisions. Each incision included in the study will be segmented into two halves; each half will be randomized to receive final skin closure with either Prineo (DERMABOND PROTAPE) or intradermal sutures. Subjects will be evaluated post-operatively at 24 hours (± 6 hours), 7 days (± 1 day), 12 - 25 days, and 90 days (± 10 days).

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Be at least 18 years of age;
• Be in good general health in the opinion of the Investigator with no conditions that would significantly impact wound healing as determined by medical history and review of recent concomitant medications;
• Be scheduled for at least one full thickness surgical incision of at least 20cm in length as part of elective abdominoplasty or body lift procedures, requiring the placement of sutures in the superficial fascia and subcutaneous tissue to relieve skin tension prior to final skin closure;
• Be willing to follow instructions for incision care as instructed by the investigator, and refrain from swimming or soaking in a tub during the first 12 - 25 days of the study;
• Agree to return for all follow-up evaluations specified in this protocol [7 days (± 1 day), 12 - 25 days, and 90 days (± 10 days)], six (± 1 month) and twelve months (± 1 month)];
• Agree not to schedule any additional elective surgical procedures that involve an incision that is randomized for inclusion in this study, until their participation in this study is complete; and
• Sign the informed consent.

Exclusion criteria

• Have peripheral vascular disease;
• Have insulin dependent diabetes mellitus;
• Be known to have a blood clotting disorder;
• Be receiving antibiotic therapy for pre-existing condition or infection;
• Be known to be HIV-positive or otherwise immunocompromised;
• Have known personal or family history of keloid formation or hypertrophy;
• Be currently taking systemic steroids;
• Have known or suspected allergy or sensitivity to cyanoacrylate, formaldehyde, tapes or adhesives
• Have incision type or location known to have an incidence of cyanosis or other healing abnormalities; and
• Be participating in any current clinical trial or have participated in any clinical trial within 30 days of enrolment in this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

83 participants in 2 patient groups

I

Experimental group

Description:

Dermabond Protape-Incision segments are randomized \& patient is own control

Treatment:

Device: Dermabond Protape (Prineo)

II

Active Comparator group

Description:

Intradermal Suture - Incision segments are randomized \& patient is own control. Investigator selected suture on the basis of standard local practice.

Treatment:

Device: Suture